<!DOCTYPE html>
<html>
  <head>
    <meta charset="utf-8">
    <title></title>
    <link rel="stylesheet" href="../../css/uswds.min.css">
    <link rel="stylesheet" href="../../css/style.css">
  </head>
  <body>

    <header>
        <h2 class="title">
            <a href="../../index.html">Code of Federal Regulations (alpha)</a>
        </h2>
    </header>

    <div class="usa-grid">
      <div class="usa-width-one-whole">
          <h3>
                                <a href="../../index.html">CFR</a><span>&nbsp/&nbsp</span>
                                <a href="../titles/title42.html">
                                    Title 42
                                </a><span>&nbsp/&nbsp</span>
                                <a href="../parts/42CFR456.html">Part 456
                                </a><span>&nbsp/&nbsp<span>
                                Sec.  456.716  DUR Board.
                            </h3>
                            <p class="depth1"><em>(a)</em> State DUR Board requirement and member qualifications. Each  State must establish, either directly or through a contract with a  private organization, a DUR Board. The DUR Board must include health  care professionals who   have recognized knowledge and expertise in at least one of the  following:</p><p class="depth2"><em>(1)</em> Clinically appropriate prescribing of covered outpatient drugs.</p><p class="depth2"><em>(2)</em> Clinically appropriate dispensing and monitoring of covered  outpatient drugs.</p><p class="depth2"><em>(3)</em> Drug use review, evaluation, and intervention.</p><p class="depth2"><em>(4)</em> Medical quality assurance.</p><p class="depth1"><em>(b)</em> Board composition. At least one-third but not more than 51  percent of the DUR Board members must be physicians, and at least one- third of the Board members must be pharmacists. These physicians and  pharmacists must be actively practicing and licensed.</p><p class="depth1"><em>(c)</em> Medicaid agency/DUR Board relationship. The Medicaid agency is  ultimately responsible for ensuring that the DUR program is operational  and conforms with the requirements of this subpart. The agency has the  authority to accept or reject the recommendations or decisions of the  DUR Board.</p><p class="depth1"><em>(d)</em> DUR Board activities. The State agency must ensure that the  operational tasks involved in carrying out the DUR Board activities set  forth at section 1927(g)(3)(C) of the Act are assigned, limited only by  the requirements of section 1927(g)(3)(C) of the Act, based on  consideration of operational requirements and on where the necessary  expertise resides. Except as limited by the requirements of section  1927(g)(3)(C) of the Act, the State agency may alter the suggested  working relationships set forth in this paragraph.</p><p class="depth2"><em>(1)</em> Application of predetermined standards: Board's activities. The  DUR Board should perform the following activities:</p><p class="depth3"><em>(i)</em> Review and make recommendations on predetermined standards  submitted to it by the Medicaid agency or the agency's contractor.</p><p class="depth3"><em>(ii)</em> Evaluate the use of the predetermined standards, including  assessing the operational effect of the predetermined standards in use,  and make recommendations to the Medicaid agency or the agency's  contractor concerning modification or elimination of existing  predetermined standards or the addition of new ones.</p><p class="depth3"><em>(iii)</em> Recommend guidelines governing written predetermined standards  that pharmacies not using approved software must use in conducting  prospective DUR.</p><p class="depth2"><em>(2)</em> Application of predetermined standards: Medicaid agency role.  The Medicaid agency or its contractor should perform the following  activities:</p><p class="depth3"><em>(i)</em> Submit predetermined standards to the DUR Board for its review  and recommendations before the Medicaid agency applies them to drug  claims data.</p><p class="depth3"><em>(ii)</em> If prospective DUR is conducted using an electronic claims  management (ECM) system, apply software approved by the Board.</p><p class="depth3"><em>(iii)</em> If prospective DUR is not conducted through an ECM system, as  part of general compliance monitoring, ensure that Medicaid  participating pharmacies conduct prospective drug review that screens  for the potential drug therapy problems listed in section 1927(g)(2)(A)  of the Act.</p><p class="depth2"><em>(3)</em> Retrospective DUR: Board's activities. The DUR Board should  perform the following activities:</p><p class="depth3"><em>(i)</em> Review and make recommendations on predetermined standards  submitted to it by the Medicaid agency or the agency's contractor.</p><p class="depth3"><em>(ii)</em> Make recommendations to the Medicaid agency or the agency's  contractor concerning modification or elimination of existing  predetermined standards or the addition of new ones.</p><p class="depth2"><em>(4)</em> Retrospective DUR: Medicaid agency role. The Medicaid agency or  its contractor should apply the predetermined standards to drug claims  data in order to generate reports that identify patterns of fraud,  abuse, gross overuse, or inappropriate or medically unnecessary care.</p><p class="depth2"><em>(5)</em> Education program (including interventions): Board's activities.  The DUR Board must perform the following activities:</p><p class="depth3"><em>(i)</em> Identify and develop educational topics if education of  practitioners on common drug therapy problems is needed to improve  prescribing or dispensing practices.</p><p class="depth3"><em>(ii)</em> Make recommendations as to which mix of the interventions set  forth in Sec.  456.711 (a) through (d) would most effectively lead to  improvement in the quality of drug therapy. The DUR board  recommendations must be   based upon an in-depth review of the results of the application of  predetermined standards against claims data reports, must be appropriate  based upon program experience, and must match the educational program  with the drug therapy problems identified.</p><p class="depth3"><em>(iii)</em> Periodically re-evaluate and, if necessary, modify the  interventions.</p><p class="depth2"><em>(6)</em> Education program (including interventions): Medicaid agency's  role. The Medicaid agency or its contractor should perform the following  activities.</p><p class="depth3"><em>(i)</em> Apply predetermined standards to drug claims data to generate  reports that provide the basis for retrospective education and  interventions and furnish those reports to the Board.</p><p class="depth3"><em>(ii)</em> Carry out the educational programs and interventions specified  by the Board.</p><p class="depth1"><em>(e)</em> Funding for the Board. FFP is available for expenses associated  with the operation of the DUR Board in carrying out its  responsibilities, and payment is made under procedures established in  part 433 of this chapter as follows:</p><p class="depth2"><em>(1)</em> If the requirements for skilled professional medical personnel  at Sec.  432.50 of this chapter are met, at the rate of 75 percent.</p><p class="depth2"><em>(2)</em> If the requirements for skilled professional medical personnel  at Sec.  432.50 of this chapter are not met, at the rate specified in  Sec.  456.719.  [57 FR 49408, Nov. 2, 1992, as amended at 59 FR 48825, Sept. 23, 1994]</p>
      </div>
    </div>

    <footer class="usa-footer usa-footer-slim" role="contentinfo">
    <div class="usa-grid usa-footer-return-to-top">
      <a href="#">Return to top</a>
    </div>
    <div class="usa-footer-primary-section">
      <div class="usa-grid-full">
        <h5>Built with ‚ù§ by <a href="https://18f.gsa.gov/">18F</a>.
          Code available <a href="https://github.com/18F/allregs">on Github.
        </a></h5>
        <h5>All regulations are from the 2015 Annual Edition.
          This is a technical demonstration not intended for serious use.</h5>
      </div>
    </div>
  </footer>
  </body>
</html>
